2020 ASCO Virtual Direct™ Highlights
2020 ASCO Improvements in Endometrial Cancer: Single Agent IO in “Non-biomarker” Selected Patients, Cabozantinib + Nivolumab in Advanced Recurrent Metastatic Disease, anti-HER-2 in Advanced or Recurrent Uterine Serous Carcinoma
By
2020 ASCO Virtual Direct™ Highlights
FEATURING
Rebecca Stone
By
2020 ASCO Virtual Direct™ Highlights
FEATURING
Rebecca Stone
Comments 0
Login to view comments.
Click here to Login
